FDA Released New Model-Informed Drug Development Guidance
The FDA issued the M15 guidance to standardize the framework for model-based drug development and documentation.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Do you believe standardized drug development models improve medicine safety and testing efficiency?
The FDA has released its M15 guidance, which outlines standardized principles for model-informed drug development (MIDD). The agency intends for this framework to assist developers in evaluating and documenting evidence derived from drug development models.
Why it matters
This guidance seeks to foster a multidisciplinary understanding of model-based development across the industry. By aligning evaluation and documentation standards, the FDA aims to create a more consistent regulatory pathway for drug submissions.
The M15 guidance establishes a formal structure for model evaluation and evidence documentation. It specifically sets benchmarks for the planning and evidentiary standards required for regulatory submissions relying on predictive modeling.
The players
Food and Drug Administration
The United States federal agency responsible for protecting public health by regulating the safety, efficacy, and security of human and veterinary drugs.
The details
The newly published guidance provides a comprehensive framework for assessing evidence generated by models during the drug development process. It is recommended for use in meeting requests and as a standard for background packages submitted to the FDA.
Timeline
October 5, 2026: The FDA published the M15 resource center guidance.
The Tech Race
The release of M15 builds upon the FDA's existing push to integrate complex simulation into the pharmaceutical pipeline. This reflects a broader industry shift toward replacing traditional, slow-moving empirical trials with validated computational models that expedite decision-making.
For pharmaceutical companies, these standards dictate how data must be organized and documented for future regulatory reviews. Developers will need to adjust their internal documentation protocols to align with these new federal expectations for model validation.
The takeaway
The move toward standardized modeling indicates a future where drug approval relies more heavily on predictive simulations than on legacy observational methods. Industry stakeholders should ensure their development models meet these harmonized benchmarks to avoid potential regulatory delays.
Further reading
For additional context on how the agency evaluates emerging medicinal technologies, visit the Biotech section.
More information
Review the full technical requirements by accessing the FDA M15 resource center guidance.
Source note: This article includes information reported by U.S. Food and Drug Administration.
Live Poll
Do you believe standardized drug development models improve medicine safety and testing efficiency?
